Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Dec. 31, 2025
shares
| |
| Trading Arrangements, by Individual | |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| David E.I. Pyott [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | David E.I. Pyott, Director On November 12, 2025, David E.I. Pyott, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Pyott, acting through a broker, may sell up to an aggregate of 7,610 shares of our common stock received upon the exercise of options granted to Mr. Pyott as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from February 11, 2026 to October 14, 2026. The plan is scheduled to terminate on October 14, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Pyott or the broker, or as otherwise provided in the plan |
| Name | David E.I. Pyott |
| Title | member of our board of directors |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | November 12, 2025, |
| Expiration Date | October 14, 2026 |
| Arrangement Duration | 245 days |
| Aggregate Available | 7,610 |
| Pushkal Garg, M.D [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Pushkal Garg, M.D., Chief Research and Development Officer On November 20, 2025, Pushkal Garg, M.D. our Chief Research and Development Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Garg, acting through a broker, may sell up to an aggregate of 25,418 shares of our common stock received upon the settlement of awards granted to Dr. Garg as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from February 27, 2026 to November 1, 2026. The plan is scheduled to terminate on November 1, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Garg or the broker, or as otherwise provided in the plan. |
| Name | Pushkal Garg, M.D |
| Title | Chief Research and Development Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | November 20, 2025 |
| Expiration Date | November 1, 2026 |
| Arrangement Duration | 247 days |
| Aggregate Available | 25,418 |
| Tolga Tanguler [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Tolga Tanguler, Chief Commercial Officer On November 14, 2025, Tolga Tanguler, our Chief Commercial Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Tanguler, acting through a broker, may sell up to an aggregate of 25,782 shares of our common stock received upon the settlement of awards granted to Mr. Tanguler as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from February 13, 2026 to November 15, 2026. The plan is scheduled to terminate on November 15, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Tanguler or the broker, or as otherwise provided in the plan. |
| Name | Tolga Tanguler |
| Title | Chief Commercial Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | November 14, 2025 |
| Expiration Date | November 15, 2026 |
| Arrangement Duration | 275 days |
| Aggregate Available | 25,782 |